Regulating the p53 system through ubiquitination

The tumor suppressor p53 is tightly controlled at low levels in cells by constant ubiquitination and proteasomal degradation. In response to stresses, ubiquitination of p53 is inhibited through diverse pathways, depending on the nature of the stimulus and cell type. This leads to the accumulation and activation of p53, which induces cell cycle arrest and/or apoptosis to prevent cells from transformation. Many studies have indicated that defects of the p53 system are present in most, if not all, human tumor cells. Meanwhile, significant progress has been made in understanding the molecular mechanisms of p53 ubiquitination and the regulation of the p53 system. Therefore, it is possible now to consider targeting ubiquitination as a means to regulate and reactivate p53 in tumors. Emerging evidence suggests that inhibiting the E3 activity of Mdm2, blocking the interaction of p53 and Mdm2, and restoring the function of mutated p53 are potential effective strategies to kill certain tumor cells selectively. It is conceivable that new chemotherapeutic agents based on these studies will be generated in the not-so-distant future.

[1]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[2]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[3]  D. Ledbetter,et al.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. , 1989, Science.

[4]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[5]  D. Lane,et al.  p53, guardian of the genome , 1992, Nature.

[6]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[7]  M. Scheffner,et al.  The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 , 1993, Cell.

[8]  Guillermina Lozano,et al.  Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 , 1995, Nature.

[9]  Lawrence A. Donehower,et al.  Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 , 1995, Nature.

[10]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[11]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[12]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[13]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[14]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[15]  U. Lopes,et al.  p53-dependent Induction of Apoptosis by Proteasome Inhibitors* , 1997, The Journal of Biological Chemistry.

[16]  F. Kashanchi,et al.  Phosphorylation of p53 Serine 15 Increases Interaction with CBP* , 1998, The Journal of Biological Chemistry.

[17]  M. Pincus,et al.  MEKK1/JNK signaling stabilizes and activates p53. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[19]  Kevin Ryan,et al.  The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.

[20]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[21]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[23]  S. Jentsch,et al.  A Novel Ubiquitination Factor, E4, Is Involved in Multiubiquitin Chain Assembly , 1999, Cell.

[24]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[26]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[27]  R. Honda,et al.  Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase , 2000, Oncogene.

[28]  D. Lane,et al.  Activation of p53 in cervical carcinoma cells by small molecules. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Shengyun Fang,et al.  Mdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53* , 2000, The Journal of Biological Chemistry.

[30]  D. Lane,et al.  An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo , 2000, Oncogene.

[31]  P. Thibault,et al.  Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. , 2000, Journal of molecular biology.

[32]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[33]  K. Engeland,et al.  The tumour suppressor protein p53 can repress transcription of cyclin B. , 2000, Nucleic acids research.

[34]  D. Lane,et al.  Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. , 2001, Experimental cell research.

[35]  M. Pincus,et al.  Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[37]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Williams,et al.  Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. , 2001, Journal of the American Chemical Society.

[39]  J. Sanes,et al.  Distinct roles of nerve and muscle in postsynaptic differentiation of the neuromuscular synapse , 2001, Nature.

[40]  W. B. Derry,et al.  Caenorhabditis elegans p53: Role in Apoptosis, Meiosis, and Stress Resistance , 2001, Science.

[41]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[42]  T. Mak,et al.  p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  T. Mak,et al.  A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Xin Lu,et al.  Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.

[45]  D. Green,et al.  A Matter of Life and Death , 2008, Science.

[46]  M. Rolfe,et al.  Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Oren,et al.  p53 Activation by Nitric Oxide Involves Down-regulation of Mdm2* , 2002, The Journal of Biological Chemistry.

[48]  Muyang Li,et al.  Acetylation of p53 Inhibits Its Ubiquitination by Mdm2* , 2002, The Journal of Biological Chemistry.

[49]  A. Haas,et al.  MdmX Is a RING Finger Ubiquitin Ligase Capable of Synergistically Enhancing Mdm2 Ubiquitination* , 2002, The Journal of Biological Chemistry.

[50]  Yoshiharu Kawaguchi,et al.  MDM2–HDAC1‐mediated deacetylation of p53 is required for its degradation , 2002, The EMBO journal.

[51]  S. Murray,et al.  The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response , 2002, Nature.

[52]  S. Volinia,et al.  The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults , 2002, Nature.

[53]  K. Tsai,et al.  p63 and p73 are required for p53-dependent apoptosis in response to DNA damage , 2002, Nature.

[54]  A. Jochemsen,et al.  Mutual Dependence of MDM2 and MDMX in Their Functional Inactivation of p53* , 2002, The Journal of Biological Chemistry.

[55]  Jiandong Chen,et al.  Transcriptional Repression of the Anti-apoptoticsurvivin Gene by Wild Type p53* , 2002, The Journal of Biological Chemistry.

[56]  R. Bernards,et al.  E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. , 2002, Cancer cell.

[57]  A. Fersht,et al.  A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  L. Neckers,et al.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. , 2002, Journal of the National Cancer Institute.

[59]  S. Minucci,et al.  Human SIR2 deacetylates p53 and antagonizes PML/p53‐induced cellular senescence , 2002, The EMBO journal.

[60]  J. Qin,et al.  Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization , 2002, Nature.

[61]  Gang Li,et al.  The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. , 2002, Experimental cell research.

[62]  W. El-Deiry,et al.  Identification and Characterization of the Cytoplasmic Protein TRAF4 as a p53-regulated Proapoptotic Gene* , 2003, Journal of Biological Chemistry.

[63]  Guillermina Lozano,et al.  Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation , 2003, Cell.

[64]  K. Anderson,et al.  Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. , 2003, Blood.

[65]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[66]  Xinbin Chen,et al.  The Activation Domains, the Proline-rich Domain, and the C-terminal Basic Domain in p53 Are Necessary for Acetylation of Histones on the Proximal p21 Promoter and Interaction with p300/CREB-binding Protein* , 2003, The Journal of Biological Chemistry.

[67]  M. Kubbutat,et al.  Regulation of HDM2 activity by the ribosomal protein L11. , 2003, Cancer cell.

[68]  Stanley N Cohen,et al.  TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  Luquan Wang,et al.  Global transcriptional program of p53 target genes during the process of apoptosis and cell cycle progression , 2003, Oncogene.

[70]  D. Livingston,et al.  Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300 , 2003, Science.

[71]  Irving L. Weissman,et al.  Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells , 2003, Nature.

[72]  Mei-Ling Kuo,et al.  Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. , 2003, Molecular cell.

[73]  N. Sogame,et al.  Drosophila p53 preserves genomic stability by regulating cell death , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Pier Paolo Pandolfi,et al.  The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation* , 2003, Journal of Biological Chemistry.

[75]  Jiandong Chen,et al.  Rescue of mutant p53 transcription function by ellipticine , 2003, Oncogene.